Fragment-Based Lead Discovery

Lead Generation Approaches in Drug Discovery

Volumn , Issue , 2010, Pages 105-139

  Albert, Jeffrey S ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Fragment detection methods NMR spectroscopy using target observed detection; Fragment optimization inhibitors of Bcl xL using NMR screening and fragment linking; Fragment based lead discovery

Indexed keywords

EID: 84876927657     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470584170.ch4     Document Type: Chapter

References (72)

1. Proudfoot, J. R. (2002). Drugs, leads, and drug-likeness: an analysis of some recently launched drugs. Bioorganic and Medicinal Chemistry Letters, 12, 1647-1650.
2. Bohacek, R. S., McMartin, C., Guida, W. C. (1996). The art and practice of structure-based drug design: a molecular modeling perspective. Medicinal Research Reviews, 16, 3-50.
3. Lipinski, C. A., Lombardo, F., Dominy, B. W., Feeney, P. J. (1997). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advances in Drug Delivery Reviews, 23, 3-25.
4. Lipinski, C. A. (2004). Lead- and drug-like compounds: the rule-of-five revolution. Drug Discovery Today Technology, 1, 337-341.
5. Teague, S. J., Davis, A. M., Leeson, P. D., Oprea, T. (1999). The design of leadlike combinatorial libraries. Angewandte Chemie International Edition, 38, 3743-3748.
6. Hann, M. M., Leach, A. R., Harper, G. (2001). Molecular complexity and its impact on the probability of finding leads for drug discovery. Journal of Chemical Information and Computer Sciences, 41, 856-864.
7. Congreve, M., Carr, R., Murray, C., Jhoti, H. (2003). A 'rule of three for fragmentbased lead discovery? Drug Discovery Today, 8, 876-877.
8. Feng, B. Y., Simeonov, A., Jadhav, A., Babaoglu, K., Inglese, J., Shoichet, B. K., Austin, C. P. (2007). A high-throughput screen for aggregation-based inhibition in a large compound library. Journal of Medicinal Chemistry, 50, 2385-2390.
9. Albert, J. S., Blomberg, N., Breeze, A. L., Brown, A. J. H., Burrows, J. N., Edwards, P. D., Folmer, R. H. A., Geschwindner, S., Griffen, E. J., Kenny, P. W., Nowak, T., Olsson, L.-L., Sanganee, H., Shapiro, A. B. (2007). An integrated approach to fragment-based lead generation: philosophy, strategy and case studies from Astra- Zeneca's drug discovery programmes. Current Topics in Medicinal Chemistry, 7, 1600-1629.
10. Bemis, G. W., Murcko, M. A. (1996). The properties of known drugs. 1. Molecular frameworks. Journal of Medicinal Chemistry, 39, 2887-2893.
11. Lepre, C. A. (2001). Library design for NMR-based screening. Drug Discovery Today, 6, 133-140.
12. Lewell, X. Q., Judd, D., Watson, S., Hann, M. (1998). RECAP-retrosynthetic combinatorial analysis procedure: a powerful new technique for identifying privileged molecular fragments with useful applications in combinatorial chemistry. Journal of Chemical Information and Computer Sciences, 38, 511-522.
13. Boehm, H.-J., Boehringer, M., Bur, D., Gmuender, H., Huber, W., Klaus, W., Kostrewa, D., Kuehne, H., Luebbers, T., Meunier-Keller, N., Mueller, F. (2000). Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hitvalidation by biophysical methods, and 3D guided optimization. A promising alternative to random screening. Journal of Medicinal Chemistry, 43, 2664-2674.
14. Baurin, N., Aboul-Ela, F., Barril, X., Davis, B., Drysdale, M., Dymock, B., Finch, H., Fromont, C., Richardson, C., Simmonite, H., Hubbard, R. E. (2004). Design and characterization of libraries of molecular fragments for use in nmr screening against protein targets. Journal of Chemical Information and Computer Sciences, 44, 2157-2166.
15. Ji, H., Stanton, B. Z., Igarashi, J., Li, H., Martasek, P., Roman, L. J., Poulos, T. L., Silverman, R. B. (2008). Minimal pharmacophoric elements and fragment hopping, an approach directed at molecular diversity and isozyme selectivity. Design of selective neuronal nitric oxide synthase inhibitors. Journal of the American Chemical Society, 130, 3900-3914.
16. Fattori, D. (2004). Molecular recognition: the fragment approach in lead generation. Drug Discovery Today, 9, 229-238.
17. Schuffenhauer, A., Ruedisser, S., Marzinzik, A. L., Jahnke, W., Blommers, M., Selzer, P., Jacoby, E. (2005). Library design for fragment based screening. Current Topics in Medicinal Chemistry, 5, 751-762.
18. Hartshorn, M. J., Murray, C. W., Cleasby, A., Frederickson, M., Tickle, I. J., Jhoti, H. (2005). Fragment-based lead discovery using x-ray crystallography. Journal of Medicinal Chemistry, 48, 403-413.
19. Hubbard, R. E., Chen, I., Davis, B. (2007). Informatics and modeling challenges in fragment-based drug discovery. Current Opinion in Drug Discovery and Development, 10, 289-297.
20. Leach, A. R., Shoichet, B. K., Peishoff, C. E. (2006). Prediction of protein-ligand interactions. Docking and scoring: Successes and gaps. Journal of Medicinal Chemistry, 49, 5851-5855.
21. Siegel, M., G., Vieth, M. (2007). Drugs in other drugs: a new look at drugs as fragments. Drug Discovery Today, 12, 71-79.
22. Makara, G. M. (2007). On sampling of fragment space. Journal of Medicinal Chemistry, 50, 3214-3221.
23. Warren, G. L., Andrews, C. W., Capelli, A.-M., Clarke, B., LaLonde, J., Lambert, M. H., Lindvall, M., Nevins, N., Semus, S. F., Senger, S., Tedesco, G., Wall, I. D., Woolven, J. M., Peishoff, C. E., Head, M. S. (2006). A Critical Assessment of Docking Programs and Scoring Functions. Journal of Medicinal Chemistry, 49, 5912-5931.
24. Hartshorn, M. J., Verdonk, M. L., Chessari, G., Brewerton, S. C., Mooij, W. T. M., Mortenson, P. N., Murray, C. W. (2007). Diverse, high-quality test set for the validation of protein-ligand docking performance. Journal of Medicinal Chemistry, 50, 726-741.
25. Maly, D. J., Choong, I. C., Ellman, J. A. (2000). Combinatorial target-guided ligand assembly: identification of potent subtype-selective c-Src inhibitors. Proceedings of the National Academy of Sciences of the United States of America, 97, 2419-2424.
26. Abad-Zapatero, C., Metz James, T. (2005). Ligand efficiency indices as guideposts for drug discovery. Drug Discovery Today, 10, 464-469.
27. Hopkins, A. L., Groom, C. R., Alex, A. (2004). Ligand efficiency: a useful metric for lead selection. Drug Discovery Today, 9, 430-431.
28. Abad-Zapatero, C. (2007). Ligand efficiency indices for effective drug discovery. Expert Opinion in Drug Discovery, 2, 469-488.
29. Leeson, P. D., Springthorpe, B. (2007). The influence of drug-like concepts on decision-making in medicinal chemistry. Nature Reviews Drug Discovery, 6, 881-890.
30. Congreve, M., Murray, C. W., Carr, R., Rees, D. C. (2007). Fragment-based lead discovery. Annual Reports in Medicinal Chemistry, 42, 431-448.
31. Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B. A., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., Joseph, M. K., Kitada, S., Korsmeyer, S. J., Kunzer, A. R., Letai, A., Li, C., Mitten, M. J., Nettesheim, D. G., Ng, S. C., Nimmer, P. M., O'Connor, J. M., Oleksijew, A., Petros, A. M., Reed, J. C., Shen, W., Tahir, S. K., Thompson, C. B., Tomaselli, K. J., Wang, B., Wendt, M. D., Zhang, H., Fesik, S. W., Rosenberg, S. H. (2005). An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature, 435, 677-681.
32. Wyss, D. F., Arasappan, A., Senior, M. M., Wang, Y.-S., Beyer, B. M., Njoroge, F. G., McCoy, M. A. (2004). Non-peptidic small-molecule inhibitors of the singlechain Hepatitis C virus NS3 protease/NS4A cofactor complex discovered by structure-based NMR screening. Journal of Medicinal Chemistry, 47, 2486-2498.
33. Congreve, M., Aharony, D., Albert, J., Callaghan, O., Campbell, J., Carr, R. A. E., Chessari, G., Cowan, S., Edwards, P. D., Frederickson, M., McMenamin, R., Murray, C. W., Patel, S., Wallis, N. (2007). Application of fragment screening by X-ray crystallography to the discovery of aminopyridines as inhibitors of bsecretase. Journal of Medicinal Chemistry, 50, 1124-1132.
34. Murray, C. W., Callaghan, O., Chessari, G., Cleasby, A., Congreve, M., Frederickson, M., Hartshorn, M. J., McMenamin, R., Patel, S., Wallis, N. (2007). Application of fragment screening by X-ray crystallography to b-secretase. Journal of Medicinal Chemistry, 50, 1116-1123.
35. Seth, P. P., Miyaji, A., Jefferson, E. A., Sannes-Lowery, K. A., Osgood, S. A., Propp, S. S., Ranken, R., Massire, C., Sampath, R., Ecker, D. J., Swayze, E. E., Griffey, R. H. (2005). SAR by MS: discovery of a new class of RNA-binding small molecules for the Hepatitis C virus: internal ribosome entry site IIA subdomain. Journal of Medicinal Chemistry, 48, 7099-7102.
36. Forino, M., Johnson, S., Wong, T. Y., Rozanov, D. V., Savinov, A. Y., Li, W., Fattorusso, R., Becattini, B., Orry, A. J., Jung, D., Abagyan, R. A., Smith, J. W., Alibek, K., Liddington, R. C., Strongin, A. Y., Pellecchia, M. (2005). Efficient synthetic inhibitors of anthrax lethal factor. Proceedings of the National Academy of Sciences of the United States of America, 102, 9499-9504.
37. Sanders, W. J., Nienaber, V. L., Lerner, C. G., McCall, J. O., Merrick, S. M., Swanson, S. J., Harlan, J. E., Stoll, V. S., Stamper, G. F., Betz, S. F., Condroski, K. R., Meadows, R. P., Severin, J. M., Walter, K. A., Magdalinos, P., Jakob, C. G., Wagner, R., Beutel, B. A. (2004). Discovery of potent inhibitors of dihydroneopterin aldolase using CrystaLEAD high-throughput X-ray crystallographic screening and structure-directed lead optimization. Journal of Medicinal Chemistry, 47, 1709-1718.
38. Howard, N., Abell, C., Blakemore, W., Chessari, G., Congreve, M., Howard, S., Jhoti, H., Murray, C. W., Seavers, L. C. A., Van Montfort, R. L. M. (2006). Application of fragment screening and fragment linking to the discovery of novel thrombin inhibitors. Journal of Medicinal Chemistry, 49, 1346-1355.
39. Card, G. L., Blasdel, L., England, B. P., Zhang, C., Suzuki, Y., Gillette, S., Fong, D., Ibrahim, P. N., Artis, D. R., Bollag, G., Milburn, M. V., Kim, S.-H., Schlessinger, J., Zhang, K. Y. J. (2005). A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design. Nature Biotechnology, 23, 201-207.
40. Saxty, G., Woodhead, S. J., Berdini, V., Davies, T. G., Verdonk, M. L., Wyatt, P. G., Boyle, R. G., Barford, D., Downham, R., Garrett, M. D., Carr, R. A. (2007). Identification of inhibitors of protein kinase B using fragment-based lead discovery. Journal of Medicinal Chemistry, 50, 2293-2296.
41. Hajduk, P. J. (2006). Fragment-based drug design: how big is too big? Journal of Medicinal Chemistry, 49, 6972-6976.
42. Hajduk, P. J., Sheppard, G., Nettesheim, D. G., Olejniczak, E. T., Shuker, S. B., Meadows, R. P., Steinman, D. H., Carrera, G. M., Jr., Marcotte, P. A., Severin, J., Walter, K., Smith, H., Gubbins, E., Simmer, R., Holzman, T. F., Morgan, D. W., Davidsen, S. K., Summers, J. B., Fesik, S. W. (1997). Discovery of Potent Nonpeptide Inhibitors of Stromelysin using SAR by NMR. Journal of the American Chemical Society, 119, 5818-5827.
43. Lepre, C. A., Moore, J. M., Peng, J. W. (2004). Theory and applications of NMRbased screening in pharmaceutical research. Chemical Reviews, 104, 3641-3675.
44. Zartler, E. R., Mo, H. (2007). Practical aspects of NMR-based fragment discovery. Current Topics in Medicinal Chemistry, 7, 1592-1599.
45. Middleton, D. A. (2006). NMR methods for characterising ligand-receptor and drug-membrane interactions in pharmaceutical research. Annual Reports on NMR Spectroscopy, 60, 39-75.
46. Dalvit, C., Fogliatto, G., Stewart, A., Veronesi, M., Stockman, B. (2001). Water- LOGSY as a method for primary NMR screening: practical aspects and range of applicability. Journal of Biomolecular NMR, 21, 349-359.
47. Geschwindner, S., Olsson, L.-L., Albert, J. S., Deinum, J., Edwards, P. D., de Beer, T., Folmer, R. H. A. (2007). Discovery of a novel warhead against b-secretase through fragment-based lead generation. Journal of Medicinal Chemistry, 50, 5903-5911.
48. Dalvit, C., Ardini, E., Flocco, M., Fogliatto, G. P., Mongelli, N., Veronesi, M. (2003). A general NMR method for rapid, efficient, and reliable biochemical screening. Journal of the American Chemical Society, 125, 14620-14625.
49. Jahnke, W., Florsheimer, A., Blommers, M. J. J., Paris, C. G., Heim, J., Nalin, C. M., Perez, L. B. (2003). Second-site NMR screening and linker design. Current Topics in Medicinal Chemistry, 3, 69-80.
50. Jahnke, W., Ruedisser, S., Zurini, M. (2001). Spin label enhanced NMR screening. Journal of the American Chemical Society, 123, 3149-3150.
51. Sharff, A., Jhoti, H. (2003). High-throughput crystallography to enhance drug discovery. Current Opinion in Chemical Biology, 7, 340-345.
52. Murray, C. W., Hartshorn, M. J. (2006). New applications for structure-based drug design. Comprehensive Medicinal Chemistry II, 4, 775-806.
53. Hofstadler, S. A., Sannes-Lowery, K. A. (2007). Interrogation of noncovalent complexes by ESI-MS: a powerful platform for high throughput drug discovery. Methods and Principles in Medicinal Chemistry, 36, 321-338.
54. Erlanson, D. A., Wells, J. A., Braisted, A. C. (2004). Tethering: fragment-based drug discovery. Annual Review of Biophysics and Biomolecular Structure, 33, 199-223.
55. Erlanson, D. A., McDowell, R. S., He, M. M., Randal, M., Simmons, R. L., Kung, J., Waight, A., Hansen, S. K. (2003). Discovery of a new phosphotyrosine mimetic for PTP1B using breakaway tethering. Journal of the American Chemical Society, 125, 5602-5603.
56. Papalia, G. A., Leavitt, S., Bynum, M. A., Katsamba, P. S., Wilton, R., Qiu, H., Steukers, M., Wang, S., Bindu, L., Phogat, S., Giannetti, A. M., Ryan, T. E., Pudlak, V. A., Matusiewicz, K., Michelson, K. M., Nowakowski, A., Pham- Baginski, A., Brooks, J., Tieman, B. C., Bruce, B. D., Vaughn, M., Baksh, M., Cho, Y. H., De Wit, M., Smets, A., Vandersmissen, J., Michiels, L., Myszka, D. G. (2006). Comparative analysis of 10 small molecules binding to carbonic anhydrase II by different investigators using Biacore technology. Analytical Biochemistry, 359, 94-105.
57. Huber, W., Mueller, F. (2006). Biomolecular interaction analysis in drug discovery using surface plasmon resonance technology. Current Pharmaceutical Design, 12, 3999-4021.
58. Cooper, M. A. (2002). Optical biosensors in drug discovery. Nature Reviews Drug Discovery, 1, 515-528.
59. Neumann, T., Junker, H. D., Schmidt, K., Sekul, R. (2007). SPR-based fragment screening: advantages and applications. Current Topics in Medicinal Chemistry, 7, 1630-1642.
60. Petros, A. M., Dinges, J., Augeri, D. J., Baumeister, S. A., Betebenner, D. A., Bures, M. G., Elmore, S. W., Hajduk, P. J., Joseph, M. K., Landis, S. K., Nettesheim, D. G., Rosenberg, S. H., Shen, W., Thomas, S., Wang, X., Zanze, I., Zhang, H., Fesik, S. W. (2006). Discovery of a potent inhibitor of the antiapoptotic protein BclxL from NMR and parallel synthesis. Journal of Medicinal Chemistry, 49, 656-663.
61. Adams, J. M., Cory, S. (1998). The Bcl-2 protein family: arbiters of cell survival. Science, 281, 1322-1326.
62. Cory, S., Huang, D. C. S., Adams, J. M. (2003). The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene, 22, 8590-8607.
63. Juin, P., Geneste, O., Raimbaud, E., Hickman, J. A. (2004). Shooting at survivors: Bcl-2 family members as drug targets for cancer. Biochimica et Biophysica Acta (BBA) Molecular Cell Research, 1644, 251-260.
64. Dominguez, D. I., De Strooper, B. (2002). Novel therapeutic strategies provide the real test for the amyloid hypothesis of Alzheimer's disease. Trends in Pharmacological Sciences, 23, 324-330.
65. Durham, T. B., Shepherd, T. A. (2006). Progress toward the discovery and development of efficacious BACE inhibitors. Current Opinion in Drug Discovery and Development, 9, 776-791.
66. Baxter, E. W., Reitz, A. B. (2005). BACE inhibitors for the treatment of Alzheimer's disease. Annual Reports in Medicinal Chemistry, 40, 35-48.
67. Schmidt, B., Baumann, S., Braun, H. A., Larbig, G. (2006). Inhibitors and modulators of b- and g-secretase. Current Topics in Medicinal Chemistry, 6, 377-392.
68. Guo, T., Hobbs, D. W. (2006). Development of BACE1 inhibitors for Alzheimer's disease. Current Medicinal Chemistry, 13, 1811-1829.
69. Dalvit, C., Pevarello, P., Tato, M., Veronesi, M., Vulpetti, A., Sundstrom, M. (2000). Identification of compounds with binding affinity to proteins via magnetization transfer from bulk water. Journal of Biomolecular NMR, 18, 65-68.
70. Edwards, P. D., Albert, J. S., Sylvester, M., Aharony, D., Andisik, D., Callaghan, O., Campbell, J. B., Carr, R. A., Chessari, G., Congreve, M., Frederickson, M., Folmer, R. H. A., Geschwindner, S., Koether, G., Kolmodin, K., Krumrine, J., Mauger, R. C., Murray, C. W., Olsson, L.-L., Patel, S., Spear, N., Tian, G. (2007). Application of fragment-based lead generation to the discovery of novel, cyclic amidine b-secretase inhibitors with nanomolar potency, cellular activity, and high ligand efficiency. Journal of Medicinal Chemistry, 50, 5912-5925.
71. Jaakola, V.-P., Griffith, M. T., Hanson, M. A., Cherezov, V., Chien, E. Y. T., Lane, J. R., Ijzerman, A. P., Stevens, R. C. (2008). The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science, 322, 1211-1217.
72. Morphy, R., Rankovic, Z. (2007). Fragments, network biology and designing multiple ligands. Drug Discovery Today, 12, 156-160.